Pentixapharm Holding AG (ETR:PTP) | Finanzwire

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 10/01/2024 at 18:53, 1 year 2 months ago

Pentixapharm Holding AG Sets IPO Placement Price at EUR 5.10 per Share

Securities Frankfurt Stock Exchange IPO Market Capitalization Pentixapharm
PRESS RELEASE

published on 10/01/2024 at 18:48, 1 year 2 months ago

EQS-Adhoc: Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed
Pentixapharm Holding AG sets IPO placement price at EUR 5.10 per share, placing all 3.9 million offer shares. Gross proceeds reach EUR 19.9 million. Post-money market capitalization at EUR 126.5 million

IPO Market Capitalization Pentixapharm Holding AG Placement Price Offer Shares
BRIEF

published on 09/23/2024 at 12:20, 1 year 2 months ago

Pentixapharm Holding AG Sets Price Range for Planned IPO

Frankfurt Stock Exchange Clinical Trials IPO Radiopharmaceuticals Pentixapharm
PRESS RELEASE

published on 09/23/2024 at 12:15, 1 year 2 months ago

Pentixapharm Holding AG Sets Price Range for Planned IPO
Pentixapharm Holding AG sets price range of EUR 4.70 to EUR 6.00 per share for planned IPO to fund product pipeline development in radioligand therapies

IPO Financial Resources Price Range Pentixapharm Holding AG Radioligand Therapies
BRIEF

published on 09/12/2024 at 15:05, 1 year 2 months ago

Pentixapharm Holding AG Plans IPO on Frankfurt Stock Exchange

Frankfurt Stock Exchange Cancer Treatment IPO Radiopharmaceuticals Phase III Trials
PRESS RELEASE

published on 09/12/2024 at 15:00, 1 year 2 months ago

Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
Pentixapharm Holding AG, a subsidiary of Eckert & Ziegler SE, plans IPO on the Prime Standard of the Frankfurt Stock Exchange, focusing on innovative radiopharmaceuticals for theranostics of various indications

Frankfurt Stock Exchange IPO Radiopharmaceuticals Pentixapharm Holding AG Theranostics

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 28 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 5 hours 33 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 3 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 58 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 3 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 1 hour 3 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 33 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 12 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 38 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 48 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 14 hours 3 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 18 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 19 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE